Final results from BIRCH, a 23-patient multicenter, randomized, open-label Phase 2a trial in spontaneous intracerebral hemorrhage, met the primary safety endpoint and showed exploratory signals of efficacy, including reduced hematoma volume and slower perihematomal edema growth versus standard of care. The data will be presented at ESOC 2026 and underpin Bioxodes’ plan for a pivotal adaptive Phase 2b/3 program.
The core move is an escalation from proof-of-concept to a registrational strategy. Bioxodes will run an adaptive Phase 2b/3 trial enrolling up to 500 patients with functional outcomes (mRS) as the primary endpoint and perihematomal edema as a key secondary. In parallel, the company is raising a €70 million Series B to finance the study, manufacturing, and registration activities. Bioxodes is engaging FDA and EMA with the view that compelling interim efficacy from the Phase 2b segment could support an accelerated pathway, pointing to late-2030 U.S. and 2031 EU approval targets if accepted.
Strategically, the company is trying to convert a biologically coherent signal into a clinically relevant path quickly in a space with no approved therapies and complex trial execution. The mechanism—a recombinant protein designed to inhibit FXIa/XIIa and neutrophil extracellular trap formation—aims to reduce secondary ischemia and neuroinflammation without exacerbating bleeding. Anchoring the pivotal design on functional outcomes while elevating perihematomal edema as a supportive biomarker is a deliberate hedge: it keeps the program anchored to patient-centric endpoints regulators expect in stroke while preserving imaging-based sensitivity to detect early biological effect sizes that can drive an adaptive design.
The plan exposes familiar tensions in acute ICH development. The Phase 2a dataset is small, open-label, and geographically narrow, so reproducibility and effect magnitude remain open questions. Regulators rarely lean on interim readouts for approval in stroke without unambiguous functional benefit; if the accelerated path is to rest partly on imaging, alignment on perihematomal edema as a decision-making marker will be critical and is not guaranteed. Operationally, a global 500-patient ICH trial demands 24/7 screening, rapid randomization within tight treatment windows, coordination with neurosurgery and ICU protocols, and rigorous management of confounders such as blood pressure control and reversal therapy. Sites will need standardized CT/MRI acquisition for volumetrics, central imaging reads, and tight protocol discipline to reduce noise. CROs with stroke network experience, rapid start-up playbooks, and strong imaging core capabilities will be essential. Technology vendors that can automate edema and hematoma quantification and streamline acute consent may have outsized impact on trial velocity. For sponsors and regulators, the program will test whether perihematomal edema can assume a consistent role as a supportive efficacy signal in ICH, joining hematoma expansion as a practical bridge between biology and function.
Near term, all eyes go to ESOC for quantitative detail: effect sizes on hematoma volume and edema trajectory, rates of hematoma expansion, and any bleeding or thrombotic safety signals at clinically relevant time points. The pivotal protocol—time-to-treat window, allowed concomitant interventions, geographic mix, adaptive rules, and powering assumptions—will reveal whether the company can realistically hit interim decision gates. Financing and manufacturing readiness for a recombinant acute therapy are additional execution risks. If regulators do not endorse an accelerated path, timelines push to a full Phase 3 readout, recalibrating the 2030–2031 targets. The broader watch item is whether ICH development can finally align biology, imaging, and functional outcomes in a way that is both operationally feasible for sites and compelling enough for regulators to move faster.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
